2024 Multiple myeloma maintenance therapy paper

Multiple myeloma maintenance therapy paper

Author: wyon

August undefined, 2024

Web11 dec. 2024 · Multiple myeloma (MM) is a malignant plasma cell disease. Maintenance treatment is beneficial to prolong survival time in patients with MM. Ixazomib was approved for the treatment of relapsed or refractory MM in combination with lenalidomide and dexamethasone. WebNational Center for Biotechnology Information

Oral ixazomib maintenance following autologous stem cell ... - PubMed

WebHere, we present updated efficacy and safety results following 12 months of maintenance therapy with lenalidomide (R) or DARA plus R (D-R). Methods: Patients with NDMM eligible for high-dose therapy (HDT) and autologous stem cell transplant (ASCT) were randomized 1:1 to RVd ± DARA, stratified by ISS stage and creatinine clearance rate ... WebInduction therapy followed by autologous stem cell transplant (ASCT) and maintenance is the current standard of care for the treatment of newly diagnosed multiple myeloma (NDMM). However, indefinite maintenance therapy after ASCT carries both significant clinical and financial toxicities. is a humidifier moisture

Multiple Myeloma NEJM

WebBackground Conflicting results have emerged, especially with respect to the impact on overall survival (OS), from trials evaluating lenalidomide maintenance (LM) therapy … WebIntroduction Maintenance therapy with lenalidomide (len) and other drugs is a cornerstone therapeutic strategy for sustaining deep durable remissions in multiple myeloma (MM). … Web1 oct. 2013 · Most of the undergoing clinical trials focus on the use of anti-CD38 antibodies in the therapy of multiple myeloma, CD19- B-cell malignancies, and NK cell … olean h\u0026r block

The era of lenalidomide maintenance therapy in multiple myeloma ...

Beth Faiman Discusses Recent Changes in Multiple Myeloma …

WebMaintenance therapy post autologous stem cell transplant (ASCT) is commonly employed in myeloma patients to prolong remission, as relapse invariably occurs after … Web24 mar. 2024 · Maintenance therapy. After ASCT, standard risk patients need lenalidomide maintenance, while bortezomib-based maintenance is needed for patients with high-risk myeloma. Management of refractory disease. Most patients require a triplet regimen at relapse, with the choice of regimen varying with each successive relapse. olean huskies footballWebConclusions: Discontinuation of maintenance therapy among patients with MM and multimodal MRD-negativity results in a high rate of sustained MRD-negativity and lack of disease progression 1 and 2 years later, with longer follow-up in progress. The results to date indicate that MRD assessed using the clonoSEQ assay with CD138-enrichment … olean in chips

"Web12 mai 2024 · A long-term analysis of an international cohort of 7291 transplantation-eligible patients with newly diagnosed MM (NDMM) showed a statistical cure fraction rate of 14.3%. 1 For transplantation-eligible patients with NDMM, the standard of care includes an induction regimen before a high-dose (HD) melphalan course with autologous stem-cell … " - Multiple myeloma maintenance therapy paper

Multiple myeloma maintenance therapy paper

Developments in continuous therapy and maintenance …

Web550 Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple … WebThe results of the most significant trials with Thal, bortezomib and lenalidomide are reported, which show high overall response rates in relapsed and refractory MM and promising results also in first-line therapy. The melphalan-prednisone regimen has been considered as standard therapy for patients with multiple myeloma (MM) for many years. Recently, …

Did you know?

WebMultiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased … Web6 oct. 2024 · Treatment for multiple myeloma (MM) is shifting increasingly to maintenance and continuous therapy, which improves outcomes versus fixed-duration treatment followed by a remission period. 1-3 Real-world data suggest that, at relapse, approximately one third of patients never receive second-line treatment, 4,5 highlighting the importance of …

WebAbstract Over the last decade, numerous drug therapies have emerged for the treatment of multiple myeloma including immunomodulating agents namely thalidomide, lenalidomide, and pomalidomide and proteasome inhibitors namely bortezomib and carfilzomib. WebA comprehensive literature search is conducted to analyze the most current literature and to provide recommendations for maintenance therapy in multiple myeloma. Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased …

Web7 dec. 2024 · Dr. Lentzsch was quick to begin her presentation clarifying that it is well defined that all myeloma patients should receive some form of maintenance therapy. There is no debate that individuals with high risk disease need intensive maintenance. Currently there is no clinical data to support either continuing or stopping maintenance … WebMultiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood...

WebPanobinostat is a treatment for multiple myeloma. It's given as a tablet over a few months, alongside bortezomib and a steroid tablet. Its main side effects include diarrhoea, fatigue and low blood counts. It can occasionally cause heart problems, but your haematologist will discuss the possible side effects with you.

Web27 nov. 2024 · A 60-year-old woman suffering from multiple myeloma (MM) was treated with zoledronic acid (bisphosphonate), dexamethasone (corticosteroid), bortezomib (a … olean injury lawyer vimeoWeb28 sept. 2024 · The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide … is a humidifier neededWeb30 nov. 2016 · The idea of maintenance therapy in multiple myeloma is not new. Starting with chemotherapy in 1975 [ Alexanian et al. 1975 ], to interferon in 1998, to novel agents recently, a multitude of agents have been explored in patients with multiple myeloma. olean in foodWeb14 sept. 2024 · The treatment outcome of patients with multiple myeloma (MM) significantly improved by the introduction of proteasome inhibitors and … olean ice rink hoursWeb8 oct. 2024 · Dr. Shah cited studies suggesting that maintenance improves progression-free survival (PFS) and may prolong overall survival (OS) in multiple myeloma. A meta-analysis of data from the IFM 2005-02, CALGB 100104, and GIMEMA RV-MM-PI-209 trials showed that lenalidomide maintenance prolonged PFS and OS. olean ice rinkWeb13 sept. 2024 · Daratumumab, a potent CD38-directed monoclonal antibody, has veritably transformed the treatment landscape of multiple myeloma.1 CASSIOPEIA, a two-part, … is a humidifier necessary for babyWebAcum 1 zi · S4 Ep63. Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape. In this episode of The Vitals, Beth Faiman, PhD, CNP, weighs in … olean intranet